IMR Press / FBS / Volume 9 / Issue 3 / DOI: 10.2741/S491

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers

Show Less
1 Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh-226031, India

*Author to whom correspondence should be addressed.


Front. Biosci. (Schol Ed) 2017, 9(3), 343–356;
Published: 1 June 2017
(This article belongs to the Special Issue Reproductive biomedicine: from basics to translational outcome)

The Poly(ADP-ribose) polymerase-1 (PARP1) is a multifunctional nuclear protein involved in a variety of cellular functions. Recently, its role in the onset, progression and therapy resistance of cancers in general and reproductive cancers in particular has been recognised. The PARP associated signaling is perceived to play a key role in the development, sustenance and relapse of reproductive cancers. This has led to the preclinical and clinical assessment of PARP inhibitors as targeted therapeutic agents in reproductive cancers. In the first part of this review, we have summarized the current status of PARP in the onset, progression and therapy resistance of reproductive cancers. In the second part of the review, we have discussed the translational applications of PARP inhibitors, underscoring the perceived therapeutic opportunities, bottlenecks and the utility of the ongoing clinical trials.

Reproductive cancers
PARP inhibitors
Drug Resistance
Clinical Trial
Back to top